Clinical implication of medroxyprogesterone acetate against advanced ovarian carcinoma: A pilot study

European Journal of Gynaecological Oncology

Volumn 29, Issue 3, 2008, Pages 252-255

  Niwa, K ^a   Onogi, K ^a   Wu, Y ^a   Mori, H ^a   Harrigan, R C ^b   Tamaya, T ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

Medroxyprogesterone acetate; Ovarian cancer; Progesterone receptor; Survival

Indexed keywords

ACETYLSALICYLIC ACID; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MEDROXYPROGESTERONE ACETATE; PACLITAXEL; PROGESTERONE;

ADD ON THERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVARY CARCINOMA; OVERALL SURVIVAL; PILOT STUDY; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MEDROXYPROGESTERONE 17-ACETATE; NEOPLASM STAGING; OVARIAN NEOPLASMS; PILOT PROJECTS; PROGNOSIS;

EID: 44349141109     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Tamakoshi K., Kondo T., Yasuya H., Hori Y., Kikkawa F., Toyoshima H.: "Trends in the mortality (1950-70) and incidence (1975-1993) of malignant ovarian neoplasm among Japanese women: analses by age, time, and birth cohort". Gynecol. Oncol., 2001, 83, 64.
2. Warwick J., Kehoe S., Earl H., Luesly D., Redman R., Chan K.K.,: "Long-term follow-up of patients with advanced ovarian cancer treated in randomized clinical trials". Br. J. Cancer, 1995, 72, 1513.
3. The international Collaborative Ovarian Neoplasm Group: "Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial". Lancet, 2002, 360, 505.
4. Adami H.O., Hsieh C.C., Lambe M., Trichopoulos D., Leon D., Persson I. et al.: "Parity, age at first childbirth, and risk of ovarian cancer". Lancet, 1994, 344, 1250.
5. La Vecchia C., Franceschi S.: "Oral contraceptive and ovarian cancer". Eur. J. Cancer Prev., 1999, 8, 297.
6. Longcope C.: "Endocrine function of the postmenopausal ovary". J. Soc. Gynecol. Invest., 2001, 8, S67.
7. Wimalasena J., Meehan D., Cavallo C.: "Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins". Gynecol. Oncol., 1991, 41, 56.
8. Bu S.Z., Yin D.L., Ren X.H., Jiang L.Z., Wu Z.J., Gao Q.R. et al.: "Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines". Cancer, 1997, 79, 1944.
9. Rodriguez G.C., Walmer D.K., Cline M.: "Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?". J. Soc. Gynecol. Invest., 1998, 5, 271.
10. Hempling R.E., Piver M.S., Eltabbakh G.H., Recio F.O.: "Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer". Am. J. Clin. Oncol., 1998, 21, 447.
11. Piver M.S., Barlow J.J., Lauin J.R., Blumenson L.E.: " Medroxyprogesterone acetate versus hydroxyprogesterone caproate in women with metastatic endometrial adenocarcinoma". Am. J. Clin. Oncol., 1980, 45, 268.
12. Ver Der Vange N., Greggi S., Burger C.W., Kenemans P., Vermorken J.B.: "Experience with hormonal therapy in advanced epithelial ovarian cancer". Acta. Oncol., 1995, 34, 810.
13. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D., Manetta A., et al.: "Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose response study by the Gynecologic Oncology Group". J. Clin. Oncol., 1999, 17, 1736.
14. Bonte J., Janssens J.P., Ide P.: "Modalities and results of a combined anti-estrogenic therapy by means of tamoxifen and medroxyprogesterone in gynecologic cancerlogy". Eur. J. Gynecol. Oncol., 1986, 7, 45.
15. Serow S.F., Scully R.E., Sobin L.H.: "International classification of tumors. Histological typing of ovarian tumours". WHO, Geneva, 1973, 37.
16. Krajewska M., Fenoglio-Preiser C.M., Krajewski S., Song K., Macdonald J.S., Stemmerman G. et al.: "Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinoma of the stomach". Am. J. Pathol., 1996, 149, 1449.
17. Mallick S., Horwitz S.B.: "A role for progesterone in multi-drug resistance". In: Parlik E.J. (ed.) Estrogens, Progestins, and Their Antagonists. Boston, Birkhauser, 1996, 123.
18. Yamamoto T., Terada N., Nishizawa Y., Petrow V.: "Angiostastic activities of medroxyprogestrerone acetate and its analogues". Int. J. Cancer, 1994, 56, 393.
19. Kammerman S., Demopoulos X.Y., Raphael C., Ross J.: "Gonadotropic hormone binding to human ovarian tumors". Hum. Pathol., 1981, 12 (suppl.), 886.
20. Zaucha R., Sosinska-Mielcarek K., Jassem J.: "Long-term survival of a patient with primarily chemo-resistant metastatic cancer treated with medroxyprogesterone acetate". Breast, 2004, 13, 321.
21. Simons J.P., Aaronson N.K., Vansteenkiste J.F., ten Velde G.P, Muller M.J. et al.: "Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study". J. Clin. Oncol., 1996, 14, 1077.